The study enrolled 9,000 patients aged ≥50 years and randomized half to Flublok Quadrivalent influenza vaccine and the other half to quadrivalent inactivated influenza vaccine produced in eggs. Study data showed Flublok protected 33% more patients than the egg-derived vaccine. Flublok produced significantly higher immune responses to the A strains of influenza (especially H3N2) in the Flublok Quadrivalent study.
Flublok is a pure influenza vaccine that does not contain egg proteins, preservatives, antibiotics, gelatin, or latex. It contains three times more antigen than traditional flu vaccines. The trivalent Flublok vaccine is currently approved for people aged ≥18 years to prevent influenza disease.
For more information call (888) 855-7871 or visit Flublok.com.